**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 90434

**Manuscript Type:** EDITORIAL

**Interleukins in liver disease treatment**

Yang M *et al*. Interleukins in liver disease therapy

Ming Yang, Chun-Ye Zhang

**Ming Yang,** Department of Surgery, University of Missouri, Columbia, MO 65212, United States

**Chun-Ye Zhang,** Bond Life Sciences Center, University of Missouri, Columbia, MO 65212, United States

**Author contributions:** Yang M and Zhang CY designed, collected data, wrote, revised, and finalized the manuscript, contributed equally, and shared the first authorship.

**Corresponding author: Ming Yang, DVM, PhD, Research Assistant Professor,** Department of Surgery, University of Missouri, Room 2203, NextGen Precision Building, 1030 Hitt Street, Columbia, MO 65212, United States. yangmin@health.missouri.edu

**Received:** December 4, 2023

**Revised:** December 22, 2023

**Accepted:** January 8, 2024

**Published online:**

**Abstract**

Cytokines play pleiotropic roles in human health and disease by regulating both innate and adaptive immune responses. Interleukins (ILs), a large group of cytokines, can be divided into seven families, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, and IL-17 families. Here, we review the functions of ILs in the pathogenesis and resolution of liver diseases, such as liver inflammation (*e.g.*, IL-35), alcohol-related liver disease (*e.g.*, IL-11), non-alcoholic steatohepatitis (*e.g.*, IL-22), liver fibrosis (*e.g.*, Il-17a), and liver cancer (*e.g.*, IL-8). Overall, IL-1 family members are implicated in liver inflammation induced by different etiologies, such as alcohol consumption, high-fat diet, and hepatitis viruses. IL-2 family members mainly regulate T lymphocyte and NK cell proliferation and activation, and the differentiation of T cells. IL-6 family cytokines play important roles in acute phase response in liver infection, liver regeneration, and metabolic regulation, as well as lymphocyte activation. IL-8, also known as CXCL8, is activated in chronic liver diseases, which is associated with the accumulation of neutrophils and macrophages. IL-10 family members contribute key roles to liver immune tolerance and immunosuppression in liver disease. IL-12 family cytokines influence T-cell differentiation and play an essential role in autoimmune liver disease. IL-17 subfamilies contribute to infection defense, liver inflammation, and Th17 cell differentiation. ILs interact with different type I and type II cytokine receptors to regulate intracellular signaling pathways that mediate their functions. However, most clinical studies are only performed to evaluate IL-mediated therapies on alcohol and hepatitis virus infection-induced hepatitis. More pre-clinical and clinical studies are required to evaluate IL-mediated monotherapy and synergistic therapies.

**Key Words:** Interleukins; Family members; Liver disease; Treatment; Clinical trials

Yang M, Zhang CY. Interleukins in liver disease treatment. *World J Hepatol* 2024; In press

**Core Tip:** Interleukins as a large group of cytokines play pleiotropic roles in liver homeostasis and disease by regulating both innate and adaptive immune responses. They can be divided into seven families, and all of them are involved in the pathogenesis and resolution of chronic liver diseases. Currently, interleukin-mediated therapies are applied in patients with hepatitis induced by alcohol or hepatitis virus infection.

**INTRODUCTION**

Cytokines coordinate both innate and adaptive immune responses, and they display pleiotropic roles in healthy and disease conditions[1]. Interleukins (ILs), a large group of cytokines, play important roles in immune cell growth, differentiation, and activation, as well as other tissue-resident cells by interacting with their receptors[2]. Acute and chronic liver diseases are characterized by liver inflammation and cell death[3,4], which are commonly associated with infiltration of different immune cells and activation of hepatic parenchymal cells to secrete ILs[5,6]. ILs as a major type of cytokines are involved in the pathogenesis and resolution of liver diseases, such as liver inflammation (*e.g.*, IL-35)[7], alcohol-related liver disease (*e.g.*, IL-11)[8], non-alcoholic steatohepatitis (*e.g.*, IL-22)[9], liver fibrosis (*e.g.*, Il-17a)[10], and liver cancer (*e.g.*, IL-8)[11].

Herein, we review the members of IL families and their functions in liver disease. Especially, we summarize the current findings for liver disease treatment by targeting different ILs in clinical trials.

**Interleukin families**

Interleukins can be divided into seven families (Table 1), including IL-1 family[12,13], IL-2 family[14,15], IL-6 family[16,17], IL-8 family[18,19], IL-10 family[20,21], IL-12 family[22,23], and IL-17 family[24,25]. All the families of interleukins are involved in the liver disease. For example, IL-1 family cytokines are implicated in liver inflammation induced by different etiologies[26,27], such as alcohol consumption, high-fat diet, and hepatitis viruses. IL-2 family members mainly regulate T lymphocyte and NK cell proliferation and activation, and the differentiation of T cells[28-30]. IL-6 family cytokines play important roles in acute phase response in liver infection, liver regeneration, and metabolic regulation, as well as lymphocyte activation[31,32]. IL-8, also known as CXCL8, is activated in chronic liver diseases, which is associated with the accumulation of neutrophils and macrophages[33,34]. IL-10 family members contribute key roles to liver immune tolerance and immunosuppression in liver disease[35,36]. IL-12 family cytokines influence T-cell differentiation and play an essential role in autoimmune liver disease[37,38]. IL-17 subfamilies contribute to infection defense, liver inflammation, and Th17 cell differentiation[39,40]. Commonly, several IL families function together in each liver disease, contributing to liver disease progression and resolution. Therefore, targeting interleukins provides therapeutic strategies for liver disease.

**Interleukin Receptors**

Cytokines such as interleukin family members can bind their receptors to activate intracellular signaling pathways (*e.g.*, Janus kinase/signal transduction and transcription activation or JAK/STAT signaling pathway) to regulate cell biological functions. Cytokine receptors are mainly classified into two classes, type 1 and type 2 receptors. Most receptors of IL family members belong to type 1 receptors (Table 2), such as IL-2 and IL-6, and IL-10 and IL-10 family cytokine (*e.g.*, IL-19) receptors belong to type 2 receptors[41,42], while IL-1 family member receptors have both type 1 and type 2 receptors[12]. Type 1 cytokine receptors have a conserved Trp-Ser-X-Trp-Ser (WSXWS) motif at their C-terminals and four conserved cysteine residues at their N-terminals, and they can interact with cytokines with four-helical bundle motifs[43]. Most type 2 cytokine receptors are heterodimers (Table 2), and their intracellular domains are linked by a Janus kinase which can activate the STAT signaling pathway44.

**IL-mediated therapies in clinical trials**

Given the important roles of ILs in liver diseases, many clinical trials are undergoing to evaluate their direct and synergistic functions in liver disease treatment. The cases (Table 3) were reviewed from the website <https://www.clinicaltrials.gov/> (accessed on December 3, 2023). To date, most studies have been performed to evaluate IL-mediated therapies on alcohol and hepatitis virus infection-induced hepatitis.

**CONCLUSION**

In summary, all seven families of ILs play pivotal roles in liver homeostasis and pathogenesis by regulating both innate and adaptive immune responses. However, current studies mainly focus on evaluating the roles of ILs in alcohol and hepatitis virus infection-induced hepatitis. Pre-clinical and clinical evaluations of IL effects in different chronic liver diseases should be further studied by testing the efficacy of interleukin monotherapy or synergistic effects with other therapies.

**REFERENCES**

1 **Leonard WJ**, Lin JX. Strategies to therapeutically modulate cytokine action. *Nat Rev Drug Discov* 2023; **22**: 827-854 [PMID: 37542128 DOI: 10.1038/s41573-023-00746-x]

2 **Justiz Vaillant AA,** Qurie A. Interleukin. StatPearls Publishing LLC., 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499840/

3 **Casulleras M**, Zhang IW, López-Vicario C, Clària J. Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. *Cells* 2020; **9** [PMID: 33302342 DOI: 10.3390/cells9122632]

4 **Luedde T**, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. *Gastroenterology* 2014; **147**: 765-783.e4 [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018]

5 **Zhang CY**, Liu S, Yang M. Treatment of liver fibrosis: Past, current, and future. *World J Hepatol* 2023; **15**: 755-774 [PMID: 37397931 DOI: 10.4254/wjh.v15.i6.755]

6 **Zhang C,** Liu S, Yang M. The role of interferon regulatory factors in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Gastroenterology Insights* **2022:** 148 [DOI: 10.3390/gastroent13020016]

7 **Gao Y**, Li L, Hu X, Zhang W, Li Y. Interleukin-35 has a Protective Role in Infectious Mononucleosis-Induced Liver Inflammation Probably by Inhibiting CD8(+) T Cell Function. *Arch Immunol Ther Exp (Warsz)* 2022; **70**: 25 [PMID: 36219249 DOI: 10.1007/s00005-022-00663-8]

8 **Effenberger M**, Widjaja AA, Grabherr F, Schaefer B, Grander C, Mayr L, Schwaerzler J, Enrich B, Moser P, Fink J, Pedrini A, Jaschke N, Kirchmair A, Pfister A, Hausmann B, Bale R, Putzer D, Zoller H, Schafer S, Pjevac P, Trajanoski Z, Oberhuber G, Adolph T, Cook S, Tilg H. Interleukin-11 drives human and mouse alcohol-related liver disease. *Gut* 2023; **72**: 168-179 [PMID: 35365572 DOI: 10.1136/gutjnl-2021-326076]

9 **Hwang S**, He Y, Xiang X, Seo W, Kim SJ, Ma J, Ren T, Park SH, Zhou Z, Feng D, Kunos G, Gao B. Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets. *Hepatology* 2020; **72**: 412-429 [PMID: 31705800 DOI: 10.1002/hep.31031]

10 **Tan Z**, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B, Sun B. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. *J Immunol* 2013; **191**: 1835-1844 [PMID: 23842754 DOI: 10.4049/jimmunol.1203013]

11 **Sun F**, Wang J, Sun Q, Li F, Gao H, Xu L, Zhang J, Sun X, Tian Y, Zhao Q, Shen H, Zhang K, Liu J. Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. *J Exp Clin Cancer Res* 2019; **38**: 449 [PMID: 31684995 DOI: 10.1186/s13046-019-1455-x]

12 **Dinarello CA**. Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunol Rev* 2018; **281**: 8-27 [PMID: 29247995 DOI: 10.1111/imr.12621]

13 **Fields JK**, Günther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. *Front Immunol* 2019; **10**: 1412 [PMID: 31281320 DOI: 10.3389/fimmu.2019.01412]

14 **Zhou Y**, Quan G, Liu Y, Shi N, Wu Y, Zhang R, Gao X, Luo L. The application of Interleukin-2 family cytokines in tumor immunotherapy research. *Front Immunol* 2023; **14**: 1090311 [PMID: 36936961 DOI: 10.3389/fimmu.2023.1090311]

15 **Liao W**, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. *Curr Opin Immunol* 2011; **23**: 598-604 [PMID: 21889323 DOI: 10.1016/j.coi.2011.08.003]

16 **Rose-John S**. Interleukin-6 Family Cytokines. *Cold Spring Harb Perspect Biol* 2018; **10** [PMID: 28620096 DOI: 10.1101/cshperspect.a028415]

17 **Jones SA**, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. *Nat Rev Immunol* 2018; **18**: 773-789 [PMID: 30254251 DOI: 10.1038/s41577-018-0066-7]

18 **Russo RC**, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. *Expert Rev Clin Immunol* 2014; **10**: 593-619 [PMID: 24678812 DOI: 10.1586/1744666X.2014.894886]

19 **Matsushima K**, Yang D, Oppenheim JJ. Interleukin-8: An evolving chemokine. *Cytokine* 2022; **153**: 155828 [PMID: 35247648 DOI: 10.1016/j.cyto.2022.155828]

20 **Wei H**, Li B, Sun A, Guo F. Interleukin-10 Family Cytokines Immunobiology and Structure. *Adv Exp Med Biol* 2019; **1172**: 79-96 [PMID: 31628652 DOI: 10.1007/978-981-13-9367-9\_4]

21 **Wang X**, Wong K, Ouyang W, Rutz S. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. *Cold Spring Harb Perspect Biol* 2019; **11** [PMID: 29038121 DOI: 10.1101/cshperspect.a028548]

22 **Sun L**, He C, Nair L, Yeung J, Egwuagu CE. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. *Cytokine* 2015; **75**: 249-255 [PMID: 25796985 DOI: 10.1016/j.cyto.2015.01.030]

23 **Ye J**, Wang Y, Wang Z, Liu L, Yang Z, Wang M, Xu Y, Ye D, Zhang J, Lin Y, Ji Q, Wan J. Roles and Mechanisms of Interleukin-12 Family Members in Cardiovascular Diseases: Opportunities and Challenges. *Front Pharmacol* 2020; **11**: 129 [PMID: 32194399 DOI: 10.3389/fphar.2020.00129]

24 **Chung SH**, Ye XQ, Iwakura Y. Interleukin-17 family members in health and disease. *Int Immunol* 2021; **33**: 723-729 [PMID: 34611705 DOI: 10.1093/intimm/dxab075]

25 **Monin L**, Gaffen SL. Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. *Cold Spring Harb Perspect Biol* 2018; **10** [PMID: 28620097 DOI: 10.1101/cshperspect.a028522]

26 **Barbier L**, Ferhat M, Salamé E, Robin A, Herbelin A, Gombert JM, Silvain C, Barbarin A. Interleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases. *Front Immunol* 2019; **10**: 2014 [PMID: 31507607 DOI: 10.3389/fimmu.2019.02014]

27 **Mirea AM**, Tack CJ, Chavakis T, Joosten LAB, Toonen EJM. IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies. *Trends Mol Med* 2018; **24**: 458-471 [PMID: 29665983 DOI: 10.1016/j.molmed.2018.03.005]

28 **Kim J**, Chang DY, Lee HW, Lee H, Kim JH, Sung PS, Kim KH, Hong SH, Kang W, Lee J, Shin SY, Yu HT, You S, Choi YS, Oh I, Lee DH, Lee DH, Jung MK, Suh KS, Hwang S, Kim W, Park SH, Kim HJ, Shin EC. Innate-like Cytotoxic Function of Bystander-Activated CD8(+) T Cells Is Associated with Liver Injury in Acute Hepatitis A. *Immunity* 2018; **48**: 161-173.e5 [PMID: 29305140 DOI: 10.1016/j.immuni.2017.11.025]

29 **Sawa Y**, Arima Y, Ogura H, Kitabayashi C, Jiang JJ, Fukushima T, Kamimura D, Hirano T, Murakami M. Hepatic interleukin-7 expression regulates T cell responses. *Immunity* 2009; **30**: 447-457 [PMID: 19285437 DOI: 10.1016/j.immuni.2009.01.007]

30 **Jeffery HC**, Braitch MK, Brown S, Oo YH. Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives. *Front Immunol* 2016; **7**: 334 [PMID: 27656181 DOI: 10.3389/fimmu.2016.00334]

31 **Schmidt-Arras D**, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. *J Hepatol* 2016; **64**: 1403-1415 [PMID: 26867490 DOI: 10.1016/j.jhep.2016.02.004]

32 **Hammerich L**, Tacke F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. *Clin Exp Gastroenterol* 2014; **7**: 297-306 [PMID: 25214799 DOI: 10.2147/CEG.S43737]

33 **Zimmermann HW**, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. *PLoS One* 2011; **6**: e21381 [PMID: 21731723 DOI: 10.1371/journal.pone.0021381]

34 **Cho YE**, Kim Y, Kim SJ, Lee H, Hwang S. Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice. *Int J Mol Sci* 2023; **24** [PMID: 37895168 DOI: 10.3390/ijms242015489]

35 **Zhang LJ**, Wang XZ. Interleukin-10 and chronic liver disease. *World J Gastroenterol* 2006; **12**: 1681-1685 [PMID: 16586534 DOI: 10.3748/wjg.v12.i11.1681]

36 **Caparrós E**, Francés R. The Interleukin-20 Cytokine Family in Liver Disease. *Front Immunol* 2018; **9**: 1155 [PMID: 29892294 DOI: 10.3389/fimmu.2018.01155]

37 **Gil-Farina I**, Di Scala M, Salido E, López-Franco E, Rodríguez-García E, Blasi M, Merino J, Aldabe R, Prieto J, Gonzalez-Aseguinolaza G. Transient Expression of Transgenic IL-12 in Mouse Liver Triggers Unremitting Inflammation Mimicking Human Autoimmune Hepatitis. *J Immunol* 2016; **197**: 2145-2156 [PMID: 27511737 DOI: 10.4049/jimmunol.1600228]

38 **Yang CY**, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, Bowlus CL, Yang GX, Leung PS, Ansari AA, Wu L, Coppel RL, Gershwin ME. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. *Hepatology* 2014; **59**: 1944-1953 [PMID: 24375552 DOI: 10.1002/hep.26979]

39 **Giles DA**, Moreno-Fernandez ME, Divanovic S. IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression. *Curr Drug Targets* 2015; **16**: 1315-1323 [PMID: 26028039 DOI: 10.2174/1389450116666150531153627]

40 **Hammerich L**, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. *Clin Dev Immunol* 2011; **2011**: 345803 [PMID: 21197451 DOI: 10.1155/2011/345803]

41 **Brooks AJ,** Dehkhoda F, Kragelund BB. Cytokine Receptors. In: Belfiore A, LeRoith D, editors. Principles of Endocrinology and Hormone Action. Cham: Springer International Publishing; 2016; 1-29 [DOI: 10.1007/978-3-319-27318-1\_8-1]

42 **Dudakov JA**, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. *Annu Rev Immunol* 2015; **33**: 747-785 [PMID: 25706098 DOI: 10.1146/annurev-immunol-032414-112123]

43 **Wang X**, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. *Annu Rev Immunol* 2009; **27**: 29-60 [PMID: 18817510 DOI: 10.1146/annurev.immunol.24.021605.090616]

44 **Morris R**, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. *Protein Sci* 2018; **27**: 1984-2009 [PMID: 30267440 DOI: 10.1002/pro.3519]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 4, 2023

**First decision:** December 17, 2023

**Article in press:**

**Specialty type:** Gastroenterology & hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chatterjee B, India **S-Editor:** Liu JH **L-Editor: P-Editor:**

**Table 1 Interleukin families in liver diseases**

|  |  |  |
| --- | --- | --- |
| **IL family** | **Members** | **Functions** |
| IL-1 | IL-1α, IL-1β, IL-18, IL-33, IL-36, IL-37, and IL-38 | Mediate inflammatory responses to a wide range of stimuli in both innate and adaptive immune systems, with pro- and anti-inflammatory functions[12,13] |
| IL-2 | IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 | Regulate T cell proliferation and activation, NK cytolytic activity, and the differentiation of regulatory T cells[14,15] |
| IL-6 | IL-6, IL-11, IL-27, IL-31, oncostatin M, leukemia inhibitory factor, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1s | Play important roles in B-cell stimulation, the balance between regulatory and effector T cells, metabolic regulation, hepatic acute phase reaction, and many neural functions[16,17] |
| IL-8 | IL-8, also known as CXCL8 | It is a member of the chemokines, which has biological functions on cells expressing CXCR1 and CXCR2 receptors, such as polymorphonuclear leukocytes (neutrophils), epithelial cells, endothelial cells, fibroblasts, and neurons[18,19] |
| IL-10 | IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26 | Display immunosuppressive functions, elicit innate defense mechanisms against viral, bacterial, and fungal infections, promote tissue repair and regeneration, and provide therapeutic targets for autoimmune diseases and cancers[20,21] |
| IL-12 | IL-12, IL-23, IL-27 and IL-35 | Regulate immune responses and influence naïve T cell differentiation in many inflammatory diseases, autoimmune diseases, and various cardiovascular diseases[22,23] |
| IL-17 | IL-17A to IL-17F (IL-17E also known as IL-25) | Defense against microbial (bacteria, fungi, and helminth) infection, recruit neutrophils, and modify T-helper cell differentiation[24,25] |

IL: Interleukins.

**Table 2 Interleukins and their receptors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Interleukin** | **type 1 receptors** | **Interleukin** | **type 2 receptors** | **Il-1 family member** | **Receptor** |
| IL-2 | IL-2Rα, IL-2Rβ, IL-2Rγ | IL-10 | IL-10Rα, IL-10Rβ | IL-1α, IL-1β | IL-1R1, IL-1R3 |
| IL-3 | IL-3Rα, CSF2Rβ | IL-19, IL-20, IL-24 | IL-20Rα, IL-20Rβ | IL-1β | IL-1R2, IL-1R3 |
| IL-4 | IL-4R, IL-2Rγ/IL-13Rα1 | IL-22 | IL-22Rα1, IL-10Rβ | IL-1Rα | IL-1R |
| IL-5 | IL-5Rα, CSF2Rβ | IL-20, IL-24 | IL-22Rα1, IL-20Rβ | IL-18 | IL-1R5, IL-1R7 |
| IL-6 | IL-6Rα, gp130 | IL-26 | IL-10Rβ, IL-20Rα | IL-33 | IL-1R4, IL-1R3 |
| IL-7 | IL-7Rα, IL-2Rγ | IL-28, IL-29 | IL-28Rα, IL-10Rβ | IL-36 | IL-1R6. IL-1R3 |
| IL-9 | IL-9R, IL-2Rγ |  |  | IL-37 | IL-1R5. IL-1R8 |
| IL-11 | IL-11Rα, gp130 |  |  | IL-38 | IL-1R6. IL-1R9 |
| IL-12 | IL-12Rβ1, IL-12Rβ2 |  |  |  |  |
| IL-13 | IL-13Rα1, IL-13Rα2, IL-4R |  |  |  |  |
| IL-15 | IL-15Rα, IL-2Rβ, IL-2Rγ |  |  |  |  |
| IL-16 | CD4, CD9 |  |  |  |  |
| IL-21 | IL-21R, IL-2Rγ |  |  |  |  |
| IL-23 | IL-12Rβ1, IL-23R |  |  |  |  |
| IL-27 | IL-27Rα, gp130 |  |  |  |  |
| IL-31 | IL-31Rα, OSMR |  |  |  |  |
| IL-34 | CSF-1R |  |  |  |  |
| IL-35 | IL-12Rβ2, gp130 |  |  |  |  |

IL: Interleukins.

**Table 3 Interleukin-mediated therapies in liver disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical trials** | **Phase** | **Liver disease** | **Interleukin therapy** |
| NCT00565539 | 1 | Chronic hepatitis C virus (HCV) infection | PEGylated recombinant interleukin 29 (PEG-rIL-29) or in combination with daily oral ribavirin (an antiviral drug) |
| NCT03882307 | 1 | Hepatitis C virus (HCV) infection | Test the association of serum levels of IL-6 and TGF-β in response to antiviral therapy (sofosbuvir and daclatasvir) for chronic hepatitis C patients |
| NCT02431312 | 1 | Chronic hepatitis B | Evaluate the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding hepatitis B surface antigen and hepatitis B core antigen) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation |
| NCT02655510 | 1/2 | Alcoholic hepatitis | To test the efficacy of F-652, a recombinant fusion protein containing human IL-22 and human immunoglobulin G2 (IgG2)-Fc produced in CHO cells in serum-free culture |
| NCT03775109 | 2 | Alcoholic hepatitis | To evaluate the potential benefits of the IL-1β antibody Canakinumab in the treatment of alcoholic hepatitis |
| NCT01988506 | 2 | Autoimmune hepatitis, and other autoimmune and auto-inflammatory diseases | Low-dose IL-2 to induce regulatory T cells |
| NCT00196586 | 2 | Chronic hepatitis C | Evaluate the efficacy and safety of the addition of IL-2 to pegylated interferon α-2a and ribavirin in patients with HCV/HIV coinfection |
| NCT01697501 | 3 | Chronic hepatitis B | Evaluating the IL-28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon α-2a |
| NCT03090035 | 3 | Chronic hepatitis C | Test IL-28B (rs12979860) genotypes in patients with chronic hepatitis C infection treated with pegylated interferon α2 plus ribavirin |
| NCT02360592 | 4 | Chronic hepatitis B | Evaluate the efficacy and safety of interferon α-2b therapy plus IL-2 and hepatitis B therapeutic vaccine compared to interferon α-2b alone |
| NCT03734783 | Observational | Chronic hepatitis B | Investigate the levels of IL-35-secreting B regulatory cells in peripheral blood cells in patients with chronic hepatitis B and their functions on Th1 and Th2 cell levels |

IL: Interleukins.